# NKX2-4

## Overview
NKX2-4 is a gene that encodes the NK2 homeobox 4 protein, a transcription factor belonging to the NKL homeobox gene family. This protein plays a crucial role in regulating gene expression and cellular differentiation, particularly within the context of hematopoietic malignancies such as acute myeloid leukemia (AML) (Nagel2021NKL). NK2 homeobox 4 is involved in complex regulatory networks, interacting with various transcription factors and genes to modulate developmental pathways. Its aberrant expression is associated with leukemogenesis, especially in the erythroblastic subtype of AML, where it influences the differentiation of megakaryocytic and erythroid lineages (Nagel2021NKL). Beyond its role in leukemia, NKX2-4 is typically expressed in the hypothalamus, pituitary gland, and testis, indicating its broader significance in developmental biology (Nagel2021NKL).

## Clinical Significance
NKX2-4 is implicated in acute myeloid leukemia (AML), particularly in the erythroblastic subtype (AML-M6). It is aberrantly expressed in the OCI-M2 cell line, where it activates a network of endothelial transcription factors, including ETV2, HEY1, IRF6, and SOX7, leading to the repression of FLI1 and activation of SIX5. This deregulation affects megakaryocytic and erythroid differentiation, contributing to leukemogenesis (Nagel2021NKL). NKX2-4's role in AML is further supported by its association with a leukemogenic network involving developmental ETS genes, impacting myeloid differentiation (Nagel2021NKL).

NKX2-4 is not typically expressed in normal hematopoietic cells but is found in the hypothalamus, pituitary gland, and testis. Its expression in AML is linked to chromosomal abnormalities, such as trisomy of chromosome 20, which may enhance its expression (Nagel2021NKL). Additionally, a chromosomal translocation involving NKX2-4 and the TCRA gene has been identified in T-cell acute lymphoblastic leukemia (T-ALL) patients, suggesting its oncogenic potential in hematopoietic malignancies (Nagel2021NKL). These findings highlight the clinical significance of NKX2-4 in understanding and potentially targeting specific AML subtypes.

## Interactions
NKX2-4, a member of the NKL homeobox gene family, is involved in various interactions that influence gene expression and cellular differentiation. In the context of acute myeloid leukemia (AML), NKX2-4 interacts with several transcription factors that regulate its expression. It is activated by transcription factors such as SOX7, IRF6, ETV2, and HEY1, which bind to its promoter region. Knockdown experiments have shown that these factors are crucial for the activation of NKX2-4 expression in AML cell lines like OCI-M2 (Nagel2021NKL).

NKX2-4 also participates in regulatory networks by interacting with other genes. It represses FLI1, a gene involved in endothelial and erythroid development, and this repression is significant in the context of AML, where NKX2-4's aberrant expression contributes to developmental disturbances (Nagel2021NKL). Additionally, NKX2-4 activates genes such as ETV2 and SIX5, which are involved in endothelial development and megakaryocytic-erythroid differentiation (Nagel2021NKL).

These interactions highlight NKX2-4's role in modulating gene expression through both direct binding to DNA and through its influence on other transcription factors, contributing to its involvement in leukemogenesis and cellular differentiation pathways.


## References


[1. (Nagel2021NKL) Stefan Nagel, Claudia Pommerenke, Corinna Meyer, and Roderick A. F. MacLeod. Nkl homeobox genes nkx2-3 and nkx2-4 deregulate megakaryocytic-erythroid cell differentiation in aml. International Journal of Molecular Sciences, 22(21):11434, October 2021. URL: http://dx.doi.org/10.3390/ijms222111434, doi:10.3390/ijms222111434. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms222111434)